Arbutus Biopharma (ABUS) Change in Accured Expenses (2013 - 2026)
Arbutus Biopharma (ABUS) posted Change in Accured Expenses of -$985000.0 for Q1 2026, down 222.21% sequentially from $806000.0 in Q4 2025, and down 121.67% YoY from $4.5 million in Q1 2025.
Arbutus Biopharma (ABUS) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported Change in Accured Expenses for 14 years, with the latest figure at -$985000.0 in Q1 2026.
- Quarterly Change in Accured Expenses fell 121.67% year-over-year to -$985000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.6 million (down 297.7% YoY) and the FY2025 annual result came in at -$2.1 million, up 22.24% from the prior year.
- Change in Accured Expenses declined to -$985000.0 in Q1 2026 per ABUS's latest filing, from $806000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $4.5 million in Q1 2025 and troughed at -$7.6 million in Q2 2025.
- A 5-year average of -$372882.4 and a median of $20000.0 in 2024 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses tumbled 456.04% in 2024, then jumped 3930.0% in 2025.
- Over 5 years, Change in Accured Expenses stood at $3.8 million in 2022, then tumbled by 87.63% to $465000.0 in 2023, then slumped by 95.7% to $20000.0 in 2024, then surged by 3930.0% to $806000.0 in 2025, then plunged by 222.21% to -$985000.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$985000.0, $806000.0, and $145000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | -1.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.62 Mn |
| Jun 30, 2026 | -1.62 Mn |
| Mar 31, 2026 | -985,000.00 |
| Mar 31, 2026 | -985,000.00 |
| Dec 31, 2025 | 806,000.00 |
| Dec 31, 2025 | 806,000.00 |
| Sep 30, 2025 | 145,000.00 |
| Sep 30, 2025 | 145,000.00 |
| Jun 30, 2025 | -7.60 Mn |
| Jun 30, 2025 | -7.60 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Dec 31, 2024 | 20,000.00 |
| Dec 31, 2024 | 20,000.00 |
| Sep 30, 2024 | -3.56 Mn |
| Sep 30, 2024 | -3.56 Mn |
| Jun 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 2.86 Mn |
| Mar 31, 2024 | -2.02 Mn |
| Mar 31, 2024 | -2.02 Mn |